Streetbeat News

Stock Prices

ROOT

Root shares are trading higher following the announcement of better-than-expected Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 9:59 pm

CZR

Caesars Entertainment's stock trades lower after the company reported a revenue miss for the first quarter.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 9:58 pm

POWL

Powell Industries' stock price increased following the announcement of their Q2 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 9:58 pm

TXG

10x Genomics shares are trading lower due to worse-than-expected Q1 results.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 9:58 pm

CLX

Clorox shares are trading lower following the announcement of worse-than-expected Q3 sales results.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 9:57 pm

TMDX

TransMedics shares are trading higher following the company's announcement of raised guidance for 2024.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 9:57 pm

DOCN

DigitalOcean's stock is trading higher following the announcement that it will be included in the S&P SmallCap 600 index.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 9:56 pm

NBIX

Neurocrine Biosciences' stock is trading higher following the FDA's approval of its INGREZZA Sprinkle capsules, a significant development for the company.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 9:56 pm

MACK

Merrimack Pharmaceuticals has announced its decision to voluntarily delist its common stock from NASDAQ. This move is significant for investors and could impact the company's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 9:40 pm

TLSI

TriSalus Life Sciences Inc. (NASDAQ:TLSI) has secured a debt financing deal with OrbiMed for up to $50 million to support growth initiatives for its TriNav Infusion System. The company received $25 million at closing, with an option for an additional $25 million based on revenue milestones. The funding aims to extend TriSalus's cash runway through 2025, support strategic expansion, and fuel growth without the immediate need for equity financing. The deal also includes a warrant for OrbiMed to purchase shares of TriSalus.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 9:37 pm